A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
Clinical trial NCT05560334 · UNKNOWN
Trial details
- NCT number
- NCT05560334
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-08
- Primary completion
- 2024-09-08
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.